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Abstract Anterior gradient 2 (AGR2) is a promising anti-
tumor target associated with estrogen receptor expression
and metastatic progression of breast cancer. Insulin-like
growth factor-1 (IGF-1) is another potent factor that sti-
mulates breast cancer progression and mediates anti-e-
strogen drug resistance. However, the precise mechanism
and connections between these two factors in breast cancer
drug resistance have not been fully elucidated. Here, for the
first time, we decipher that IGF-1 remarkably induces
AGR2 in the MCF7 cell line, through an estrogen response
element (ERE) between -802 and -808 bp and a leucine
zipper transcription factor-binding site located between
-972 and -982 bp on the AGR2 promoter. We also found
that the ERK1/2 and AKT pathways mediate estrogen re-
ceptor-a at the upstream of ERE and that the JNK pathway
activates the leucine zipper site through the c-Jun/c-Fos
complex. Additionally, our data suggest that knockdown of
AGR2 reduces IGF-1-induced cell proliferation, migration
and cell cycle progression. Therefore, we report that AGR2
is a key modulator involved in IGF-1-induced breast cancer
development. We propose that the identification of the
mechanism linking the IGF-1/insulin signal and AGR2
promoter activation is important, because it provides in-
sights into the development of anti-breast cancer drugs.
Keywords Anterior gradient 2  Insulin-like growth
factor-1  Breast cancer  Estrogen response element 
Activator protein-1 site
Introduction
Anterior gradient-2 (AGR2), also known as HAG-2, is the
human homologue of Xenopus laevis cement gland protein
XAG-2 [1] and nAG, which is responsible for limb regen-
eration in the newt [2]. AGR2 has been reported to be
overexpressed in several human cancers [3], including
estrogen receptor (ER)-positive breast cancer. AGR2 over-
expression in breast cancer cells promotes cell migration and
malignant transformation [4]. The clinical and prognostic
significance of AGR2 has been demonstrated, suggesting its
potential as a tumor diagnostic marker [5] and amodulator in
breast cancer anti-estrogen drug resistance [6].
However, the full spectrum of factors and mechanisms
regulating AGR2 levels in tumor cells are still poorly un-
derstood. Strikingly, AGR2 expression is increased over
sevenfold in the presence of estrogen in hormone-depen-
dent breast cancer cells [7]. A possible mechanism was
recently proposed to explain this estrogen-induced ex-
pression of AGR2 [8]. In that study, AGR2 expression was
reported to be activated by estradiol, through the binding of
ER to the estrogen response elements (ERE) located in the
potential transcriptional regulatory region of AGR2 pro-
moter. In addition to the estrogen receptor, current research
on AGR2 using promoter analysis also identified the
transcription factors Foxa1 and Foxa2 as major players in
regulating AGR2 promoter activity [9]. The ErbB3-binding
protein 1 (EBP1)—Foxa signal circuit [10]—was also re-
ported as playing a significant role in AGR2 promoter
modulation.
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The insulin-like growth factor (IGF-1)/insulin signaling
axis has widely been reported in modulating breast cancer
anti-estrogen drug resistance [11]. Binding of IGF-1 to its
receptor activates receptor tyrosine kinase activity, leading
to the phosphorylation of key downstream effectors such as
insulin receptor substrate proteins-1 (IRS-1) [12] and insulin
receptor substrate proteins-2 (IRS-2) [13] as well as Src
homology collagen (SHC) [14]. Significantly, cross talk
between the IGF-1 receptor and estrogen receptor-a has also
been reported as a requirement for the rapid activation of the
IGF-1 receptor via specific signaling cascades in breast
cancer [15]. In addition, many pathways have been reported
to be highly involved in IGF-1-induced anti-estrogen drug
resistance, including PI3K/AKT [16] and mTOR [17].
However, the specific modulator related to IGF-1-induced
breast cancer development is still poorly understood.
Our findings suggest AGR2 induction as a novel IGF-1-
induced breast cancer formation mechanism, relevant to
both the activation of the ER and the non-ER pathways.
These results provide further insights toward the develop-
ment of anti-estrogen drug-resistant tumors and their po-
tential therapeutic targets.
Materials and methods
Cell culture and treatment
The MCF7 cell line (ATCC HTB-22) was obtained from
the American Type Culture Collection (ATCC, Manassas,
VA, USA). Cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM, Invitrogen) with 10 % fetal
bovine serum (FBS, Gibco Life Technologies) and peni-
cillin streptomycin (Solarbio). Before treatment, cells were
transferred from 10-cm plates to 6-well plates and were
serum-starved for 24 h with DMEM without phenol red
(Gibco Life Technologies). Treatments included b-estra-
diol (E2, Sigma-Aldrich), insulin-like growth factor-1
(IGF-1, Genescript) and insulin (Solarbio) in the same
medium for 24 h or 15 min. Anti-estrogen drugs include
tamoxifen and doxorubicin from Thermo, as well as
raloxifene and fulvestrant from Selleckchem. In addition,
chemical inhibitors included U0126-EtOH (MEK in-
hibitor), fulvestrant (ICI 182,780, estrogen receptor-a in-
hibitor) and MK2206 2HCl (AKT inhibitor), and SP00125
(JNK Inhibitor) and OSI-906 (IGF-1 receptor inhibitor),
which were also purchased from Selleckchem, while mo-
nensin was from Beyotime.
Protein extraction and western blotting
After treatment, cells were lysed in NP-40 lysis buffer.
Proteins were separated using SDS-PAGE and transferred
onto nitrocellulose membrane for antibody detection. The
primary antibodies included b-actin from Santa Cruz
Biotechnology; AKT and phosphor-AKT from Epitomics;
and p44/42 MAPK, phosphor-p44/42 MAPK, estrogen re-
ceptor-a, phosphor-estrogen receptor-a and JNK from Cell
Signal Technology. In addition, the monoclonal antibody
against AGR2, 18A4, was prepared by our laboratory. The
secondary antibodies included goat anti mouse and rabbit
from Odyssey. Fluorescence was detected with infrared
imaging scanner (Odyssey).
shRNA knockdown
AGR2 knockdown in MCF7 cells was performed using an
isopropyl b-D-1-thiogalactopyranoside-inducible AGR2
shRNA lentiviral construct. Cells were infected with AGR2
shRNA lentiviral construct or a control vector and selected
using puromycin after 48 h. Stably transfected cell lines
were grown in the presence of 1 mM b-D-1-thiogalac-
topyranoside for 7 days to induce shRNA expression.
iCell proliferation assay
Baselines were first measured by adding DMEM into
iCelligence (ACEC Biosciences) sensor wells. Cells were
counted first with a hemocytometer and added to each
sensor well up to 10,000 cells per well. After the curves
showed stable changes, which indicate cell adherence,
different treatments were added to each well. The prolif-
eration rates are indicated by the slope of the growth curve.
Flow cytometry assay
Cells were treated in different conditions and fixed in 70 %
ethanol for 12 h. The samples were analyzed using a
FACSCanto flow cytometer (Becton–Dickinson), and
FlowJo software was used to analyze the cell cycle
distribution.
Plasmid construction and mutagenesis preparation
The AGR2 promoter-luciferase (AL) plasmid was con-
structed by ligation of pGL3-basic vector and AGR2 se-
quence, and mutagenesis was performed using the KOD-
Plus-Mutagenesis Kit (Toyobo). The sequences of the de-
signed mutagenesis primers are shown in Table 1. The
pGL3-basic vector (Promega) without the AGR2 promoter
sequence served as a negative control.
Transfection and dual-luciferase assay
The transfection was performed using PEI (Polysciences,
Inc.) according to the CELLTECH’s protocol with
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modification. A reporter plasmid (2 lg) with 0.2 lg of
pRL-TK (Promega) served as an internal control for each
well in 6-well plates. In 5 h after transfection, the cells
were incubated in fresh DMEM for over 12 h and trans-
ferred to 96-well plates. Then, the cells were exposed to
different treatments for 24 h and assayed for luciferase
activity using a dual-luciferase assay system (Promega).
The luciferase intensity of the reporter gene and pRI-TK
were measured with an automatic-sampling microplate
reader (Thermo Fisher Scientific).
RT-PCR
Total RNA was isolated from cells after 24 h of treatment,
and the RNA content was measured. Reserve transcription
was performed followed by ReverseTra Ace qPRC RT Kit
(Toyobo). The gene-specific RT-PCR, targeting AGR2 and
GAPDH, was conducted with ThunderBird SYBR qPCR
Kit (Toyobo) and Applied Biosystems Real-Time PCR
Instrument (Life Technology). The sequences of the de-
signed mutagenesis primers are shown in Table 2.
Fig. 1 IGF-1 induces AGR2 expression in a dose-dependent manner
in MCF7 cells. a MCF7 cells were treated with 10 nM IGF-1 and
5 lg/ml insulin for five different time intervals (6, 12, 18, 24 and
30 h). AGR2 levels were determined with a western blot assay.
b AGR2 expression induced by IGF-1 without E2 was detected via
immunofluorescence in MCF7 cells using confocal microscopy. Cells
were starved for 24 h before IGF-1 treatment. The nuclei were stained
with DAPI (blue) as an internal reference, and AGR2 was stained
with specific primary antibody (red). The IOD value of red
fluorescence was quantified using Image-Pro, normalized to blue
fluorescence and set in the right panel in the form of a histogram. The
original magnification is 9400. c MCF7 cells were treated with
20 lg/ml CHX with or without 10 nM IGF-1 for six different time
periods (0, 4, 8, 12, 16 and 20 h). A western blot assay was utilized to
show the degradation rate of AGR2 in both groups. Relative AGR2
levels are shown in the right panel. d Relative AGR2 mRNA level of
MCF7 cells compared with GAPDH was determined using RT-PCR
after 24 h of treatment with 10 and 20 nM IGF-1. e Dose-responsive
IGF-1 activation of AGR2 transcription was confirmed by a 1.9 kb of
AGR2 promoter-luciferase reporter assay with a pRL-TK plasmid co-
transfected into MCF7 cells and treated with four different concen-
tration of IGF-1 (1, 10, 20 and 50 nM). The luciferase intensity was
detected with a microplate reader and normalized to the intensity of
Renilla. The pGL3-basic vector was detected as a negative control.
Each experiment was repeated at least three times. *P\ 0.05;
**P\ 0.01; ***P\ 0.0001
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The mRNA fold changes were calculated according to the
DDCt value.
Immunofluorescence assay
MCF7 cells grown on coverslips were fixed with 4 %
formaldehyde for 10 min and blocked with goat serum for
30 min. Coverslips were incubated with the AGR2 anti-
body for 2 h and washed with PBS. They were incubated
with secondary antibody conjugated with Dylight488
(MutiSciences Biotech). Nuclei were counterstained using
DAPI (Invitrogen). The fluorescence was observed and
captured with laser confocal microscopy (Leica Camera).
Wound-healing assay
MCF7 cells were seeded on a 6-well plate with a near
100 % intensity and starved in serum-free DMEM for 12 h.
Gaps were created in a cross shape with pipette tips in the
middle of each well. Images of each gap were captured 0
and 24 h after different treatments. The migration rate was
calculated by the ratio of average migration distance at
24 h to the original gap distance at 0 h, measured in pixels.
Statistical analysis
All values are expressed as the mean ± standard deviation
(SD). The Origin 9.0 Pro program (OriginLab, US) was
used for all statistical analyses and graph drawing. Two-
tailed Student’s t test was used to compare measurements
of pairs of samples if appropriate.
Results
IGF-1 induces AGR2 expression in a dose-
dependent manner in MCF7 cells
It has been widely reported that AGR2 can be induced in the
exposure of hormones [18] or physiological stress [19]. Here,
Fig. 2 An estrogen response element and a leucine zipper-binding
site are both required for AGR2 promoter activation by IGF-1.
a AGR2 promoter deletion mutations were analyzed by luciferase
reporter assays. Luciferase reporter constructs containing different
length of AGR2 promoter sequence were co-transfected with pRL-TK
control plasmid into MCF7 cells. Cells were then treated with 10 nM
IGF-1 and 20 nM IGF-1 for 18 h without E2. The fluorescence
intensity of cell extracts was recorded by microplate reader and
normalized by control Renilla luciferase activity. b AGR2 promoter
with 100-base pair scanning deletions were analyzed for IGF-1 effects
similarly as in (a). c The Transfac database was used to analyze the
potential transcriptional binding sites indicated within the target
sequences identified by (a, b), and site-specific mutagenesis were
designed based on the result of bioinformatics analysis. d, e Se-
quence-specific mutations designed to destroy potential transcription
factor-binding sites in D4 (d) and D5 (e) according to (c) were used in
this promoter assay. After transfection, the cells were treated with
control PBS, 10 nM IGF-1, 5 nM E2 and the mixture of IGF-1 and E2
for 18 h. The pGL3-basic vector was used as a negative control. Each
experiment was repeated at least three times. *P\ 0.05; **P\ 0.01;
***P\ 0.0001. TF
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we treated MCF7 cells with a significant breast cancer-re-
lated growth factor, IGF-1, in a time course, from 6 to 30 h.
We compared the induction level with insulin, a structural
analogue of IGF-1 (Fig. 1a). The data indicated that IGF-1
has a more rapid and stronger AGR2 induction than insulin in
MCF7 cells. In addition, an immunofluorescence assay re-
vealed that the IGF-1 induction of AGR2 occurred in a dose-
dependent manner at protein level (Fig. 1b).
To determine whether this increase in AGR2 expression
caused by IGF-1 is relevant to protein degradation, we
Table 1 Sequence of primers
of different mutagenesis on
AGR2 promoter
Mutagenesis Primer sequence
D1 Antisense: 50 CTAGCACGCGTAAGAGCTCGGTACC 30
Sense: 50 GTCATTTAATATTCAAAATGGTCCC 30
D2 Antisense: 50 CTAGCACGCGTAAGAGCTCGGTACC 30
Sense: 50 GAATTGAAAGGAAATTCAGTATT 30
D3 Antisense: 50 CTAGCACGCGTAAGAGCTCGGTACC 30
Sense: 50 CTCAGTTTTGAAAAATTACGTGGG 30
FL-D1 Antisense: 50 GACTTTTCCCTGTATTGCCACATGG 30
Sense: 50 CTATGAGCAAGCACCAGGATGCAGG 30
FL-D2 Antisense: 50 GATCTGAGATCTCATTTAACATCCC 30
Sense: 50 GTCCCAACTCTGCCCTAAACTAGTT 30
FL-D3 Antisense: 50 CAAAGTCCTTCAGTCCCTTATCCAC 30
Sense: 50 TATTACAAGGGTCTATCTAAGGGCC 30
FL-D4 Antisense: 50 CAATTCCAGTCTTTCATTTTACAGATG 30
Sense: 50 GAAAGGAAATTCAGTATTTGGAGAATC 30
FL-D5 Antisense: 50 CTAATGAATTTATAGAAGTAATTTCTTC 30
Sense: 50 CATTTTAAAAAGTCATTTATATAGG 30
FL-D6 Antisense: 50 GAGTTAAGGTCATAATATTTCAAAAAC 30
Sense: 50 GCACACAACTTCATGAACAAAATAC 30
FL-D7 Antisense: 50 GCAGTCTTTAAAAGCTCAGAATGAAG 30
Sense: 50 GGGAAAAAAAACTTGGTTGCAGACC 30
FL-D8 Antisense: 50 CTCAAGACCATTTAATTACTCCCTG 30
Sense: 50 CTGTGAAATACCTTTGAACTCTGTG 30
FL-D9 Antisense: 50 CTTATTTAAAGGCAAACTTTCCTGC 30
Sense: 50 GACAGGAGCAGGGAAGTATTGTAG 30
M1 Antisense: 50 CGGCAATTCCAGTCTTTCATTTTAC 30
Sense: 50 CCGACAAGGGTCTATCTAAGGGCCTG 30
M2 Antisense: 50 CGCCAATTCTTAAAACTAGCAGGCC 30
Sense: 50 GGCCATCATCGTTTTCAAACTCCTG 30
M3 Antisense: 50 GCGATTTGAGCAAAATTCTTAAAACTAG 30
Sense: 50 GCGTTTCAAACTCCTGAAGAAATTACTTC 30
M4 Antisense: 50 GGGCTTCAGGAGTTTGAAAACGATG 30
Sense: 50 GGGCTTCTATAAATTCATTAGAATTGAAAGG 30
M5 Antisense: 50 GGGGTATAGAAGTAATTTCTTCAGGAG 30
Sense: 50 GGGGAGAATTGAAAGGAAATTCAGT 30
M6 Antisense: 50 CGAACTTGAATTCTGTGGGCAAAATC 30
Sense: 50 GGGTGGAAAAATATACATACTTGCAAATG 30
M7 Antisense: 50 GGAATAAATCCTTGAATTCTGTGGG 30
Sense: 50 GGAAATATACATACTTGCAAATGTTTTTG 30
M8 Antisense: 50 GGGGAAAAACATTTGCAAGTATG 30
Sense: 50 GGGTATGACCTTAACTCATTTTAAAAAG 30
M9 Antisense: 50 GGGTAATATTTCAAAAACATTTGCAAG 30
Sense: 50 GGGGAACTCATTTTAAAAAGTCATTTATATAG 30
The primers sequences in the above table are used for PCR process of preparation of corresponding
mutagenesis
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performed a cycloheximide degradation assay (Fig. 1c).
The relative AGR2 level descent did not show any sig-
nificant difference in the presence of IGF-1. We also de-
tected this induction using an RT-PCR assay (Fig. 1d). The
results confirmed the IGF-1 dose-dependent induction of
AGR2 at the mRNA level. To further determine whether
the dose-dependent induction also occurred at the tran-
scriptional level, we used a 1.9 kb AGR2 promoter-lu-
ciferase construct to study the activation effect of IGF-1
(Fig. 1e). The promoter activity also increased in the
presence of IGF-1 in a dose-dependent manner, with
maximum stimulation at 20 nM. To conclude, IGF-1 shows
a significant induction of AGR2 at the expression, the
transcription and the mRNA level rather than due to
changes in degradation.
An estrogen response element and a leucine zipper-
binding site both are required for AGR2 promoter
activation by IGF-1
There are abundant reports on the modulation of AGR2
expression in breast cancer [20]; however, AGR2 promoter
activation by IGF-1 has not been reported. Therefore, we
further investigated the specific modulation sites on the
AGR2 promoter responsive to IGF-1 induction. A series of
AGR2 promoter deletion mutations linked to luciferase
reporter were constructed to identify potential IGF-1-re-
sponsive elements (Fig. 2).
Deletion from -1336 to -413 abolished the IGF-1 ef-
fect on AGR2 promoter (Fig. 2a), indicating the existence
of a major responsive element in this segment. We further
identified two different regions that may be responsible for
IGF-1 activation, -1011 to -912 (D4) and -911 to -797
(D5). A scanning deletion mutagenesis with approximately
100-base pair overlapping deletions from -1307 to -282
was performed on the AGR2 promoter. (Figure 2b).
Further identification of the potential roles of tran-
scription factor-binding sequences was conducted by site-
specific mutagenesis, which abolished 9 transcription fac-
tor-binding sites in the D4 and D5 regions. We identified
them through the analysis of the transcription factor-bind-
ing site’s database Transfac [21] (Fig. 2c). Analysis of
these promoter mutations showed that three transcriptional
regulatory elements were critical, to different degrees, for
IGF-1 and E2 activation of the AGR2 promoter in the D4
region (Fig. 2d) and in the D5 region (Fig. 2e).
According to the results shown in Fig. 2d, mutation M3,
which abolished a leucine zipper element, also abolished
the IGF-1 stimulation effect. The leucine zipper element is
suggested to be critical for the IGF-1-induced response.
Figure 4E showed that M6, which lost the HOX-PBX/
homeodomain/STAT complex-binding site between -894
and -888 bp, also showed a reduction approximately 50 %
in promoter activity in response to both IGF-1 and E2.
With the abolishing of a highly homologous estrogen re-
sponse element located between -808 and -802 bp, M9
showed almost no response to either E2 or IGF-1
stimulation. The result suggested that this ER-binding site
is indispensible in E2- and IGF-1-induced AGR2 tran-
scriptional regulation, similar to M6.
Estrogen-independent activation of AGR2 by IGF-1
requires estrogen receptor and activation of ERK
and AKT pathways
To further elucidate AGR2 activation through the IGF-1
signaling cascade upstream of estrogen response element
on the AGR2 promoter, inhibitors for the key components
of the ERK, AKT and estrogen pathways were used in a
series of western blot and luciferase assays (Fig. 3). The
results revealed that IGF-1 induces AGR2 expression with
or without E2. Additionally, the inhibition of MEK, a key
Table 2 Primers sequence of
RT-PCR assay
RT-PCR target Primer sequence
AGR2 Antisense: 50 GGAGGACAAACTGCTCTGCCAA 30
Sense: 50 TCCAAGACAACAAACCCTTG 30
BCAR1 Antisense: 50 CTGGAAAAGGGCAGCATCAC 30
Sense: 50 CTATGGGCCGTGACACCTC 30
BCAR2 Antisense: 50 CTATGGTCATGCCCGTGTCTG 30
Sense: 50 TTCCTGGGGATTTCGAGCAC 30
GAPDH Antisense: 50 TGATGGCATGGACTGTGGTCATGAG 30
Sense: 50 CTCCTGCACCACCAACTGCTTAGC 30
The primers sequences in the above table are used for RT-PCR process for detecting the mRNA level of
target gene
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Fig. 3 Estrogen-independent activation of AGR2 by IGF-1 requires
estrogen receptor and activation of ERK and AKT pathways. a, b and
d, e MCF7 cells were incubated for 24 h in different treatments with
IGF-1 and MEK, ER and AKT inhibitors. The concentration of IGF-1
is 10 nM in each group. MEK inhibitor U0126 (10 lM), ER inhibitor
ICI 182, 780 (10 nM) and AKT inhibitor MK2206 (500 nM) and E2
(5 nM) were used. Level of AGR2 protein was detected by western
blot with specific antibodies. b-Actin was detected as a loading
control. c, f Luciferase construct with 1.9 kb of AGR2 promoter
sequence and a pRL-TK control plasmid was co-transfected into
MCF7 cells and treated with different inhibitors with or without the
presence of 10 nM IGF-1 and 5 lM E2. The luciferase activity was
detected with microplate reader and normalized by Renilla activity.
g AGR2 expression induced by IGF-1 without E2 in the presence of
four chemical inhibitors was detected by immunofluorescence in
MCF7 cell by confocal microscopy. The inhibitor concentration was
10 lM U0126, 10 nM ICI 182,780, 500 nM MK2206 and 5 lM OSI-
906. Cells were starved for 24 h before IGF-1 treatment. Nuclei were
stained with DAPI (blue) as an internal reference, and AGR2 was
stained with specific primary antibody (red). The IOD value of red
fluorescence is quantified by Image-Pro, normalized to blue fluores-
cence and set in the right panel in the form of a histogram. The
original magnification is 9200. Each experiment was repeated at least
three times. *P\ 0.05; **P\ 0.01
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upstream regulator of ERK1/2, by U0126 or the inhibition
of ER by ICI 182, 780, an ER inhibitor also called Ful-
vestrant, partially abrogated AGR2 induction by IGF-1 in
western blot analysis (Fig. 3a).
We also examined the status of ER and ERK with IGF-1
and inhibitor treatments. Although U0126 treatment re-
duced ER phosphorylation, ER inhibition by ICI did not
significantly reduce phosphorylated ERK, indicating that
ER phosphorylation is downstream of ERK phosphoryla-
tion (Fig. 3b). An AGR2 promoter-reporter assay further
confirmed the effects, showing that inhibition at the tran-
scriptional level (Fig. 3c).
Another significant pathway we investigated was the
AKT pathway, which has been well reported as a key
substrate downstream of the IGF-1 receptor [22]. We used
the AKT inhibitor, MK2206, to identify the role of this
pathway in IGF-1/AGR2 signaling. A western blot assay
for AGR2 indicated that either the AKT or ER pathway
abolished the ability of IGF-1 to up-regulate AGR2 ex-
pression. The results pointed out that AKT pathway also
participates in IGF-1–AGR2 regulation (Fig. 3d). A west-
ern blot for phosphorylated ER and AKT revealed that
inhibition of AKT abolished ER phosphorylation, whereas
inhibition of ER did not influence the AKT phosphoryla-
tion. It suggested that ER activation is downstream of AKT
phosphorylation in IGF-1 signaling (Fig. 3e). To confirm
this result at the transcriptional level, a luciferase assay was
conducted. The result showed a striking abolishment of
IGF-1 stimulation under the treatment of ICI, MK2206 or
both at the transcriptional level (Fig. 3f).
To further investigate the contribution of these signaling
pathways in AGR2 induction by IGF-1, we used an in situ
immunofluorescence assay with four chemical inhibitors to
detect the AGR2 expression (Fig. 3g). The results showed
that the blockage of ERK, AKT and ER-a can partially
inhibit the IGF-1 induction of AGR2, whereas blocking
IGF-1 receptor fully inhibited this effect. In conclusion, the
data indicated that AGR2 induction by IGF-1 was entirely
through the IGF-1 receptor pathway, which involved ERK,
AKT and ER pathways.
Fig. 4 IGF-1 stimulates AGR2 expression through AP-1 site on the
AGR2 promoter. a MCF7 cells were incubated for 24 h in different
treatments with IGF-1 and JNK and ER inhibitors. The concentration
of IGF-1 is 10 nM in each group. SP00125 at the concentration of
5 lM was used. Level of AGR2 protein was detected by western blot
with specific antibodies. b-Actin was detected as a loading control. b,
c AGR2 expression induced by IGF-1 without E2 in the presence of
four chemical inhibitors was detected by immunofluorescence in
MCF7 cell by confocal microscopy. The inhibitor, SP00125,
concentration was 5 lM. Cells were starved for 24 h before IGF-1
treatment. Nuclei were stained with DAPI (blue) as an internal
reference, and AGR2 and c-Jun were stained with specific antibody
(red). The IOD value of red fluorescence is quantified by Image-Pro,
normalized to blue fluorescence and set in the right panel in the form
of a histogram. The original magnification is 9200 for AGR2 and
9100 for c-Jun. Each experiment was repeated at least three times.
*P\ 0.05; **P\ 0.01
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IGF-1 stimulates AGR2 expression through AP-1
site on the AGR2 promoter
In addition to the estrogen response element, we also
identified the leucine zipper transcription-binding site as a
potential transcriptional element. Among all potential leu-
cine zipper-binding sites, the AP-1-binding site associated
with c-Jun/c-Fos through the JNK pathway [23] has been
widely reported to relate to IGF-1 receptor [24]. Therefore,
we used Sp00125, a selective JNK inhibitor, to investigate
the pathway with western blot and immunofluorescence
assays (Fig. 4).
The result reveals that the inhibition of both c-Jun at the
downstream and ER-a with Sp00125 or ICI 182, 780 par-
tially abrogate the induction of AGR2 by IGF-1(Fig. 4a).
This abrogation effect on AGR2 induction by c-Jun
Fig. 5 AGR2 is required for IGF-1-induced cell proliferation,
migration and cell cycle progression. a MCF7 cells were transfected
with AGR2 shRNAs or a control shRNA and grown for 14 days in
puromycin selection. Western blotting of day 14 whole-cell lysates
was performed using AGR2 monoclonal antibody that recognizes
AGR2. b-Actin was used as a loading control. b RNA was isolated
from two clones of shAGR2 cells and shControl cells. cDNA was
prepared with a reverse PCR kit and used for real-time PCR with
SYBR dye and specific primers. The DDCt values in shAGR2 cells
were calculated to show the fold increase compared with shControl
cells. GAPDH was used as an internal control. c shAGR2 and
shControl cells were seeded into six-well plates. A wound in the cells
was created with a pipette tip after adherence. The wound widths
were recorded under microscopy at 0 and 24 h after treatment with or
without 10 nM IGF-1. The migratory distances of all four fringes
were then measured according to the pixels on the image directly, and
the migration rates were calculated according to the average ratio of
migration distances to original wound widths. d An iCell proliferation
assay was performed on shAGR2 and shControl cells with or without
10 nM IGF-1 treatment. Cell index proliferation curves were
generated from 20 h of real-time monitoring. e shAGR2 and
shControl cells were seeded into six-well plates and starved in
serum-free medium for 24 h. Then, the cells were treated with or
without 10 nM IGF-1 for another 24 h and fixed in 70 % ethanol for
12 h. Afterward, they were stained with propidium iodide, and the
cell cycle distributions were determined using FACSCanto. Cell cycle
distributions were further analyzed using FlowJo software. Each
experiment was repeated at least three times. *P\ 0.05; **P\ 0.01;
***P\ 0.0001
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inhibition was confirmed by an in situ immunofluorescence
assay in MCF7 cells (Fig. 4b). Furthermore, in an im-
munofluorescence assay on the location changes of c-Jun,
we showed that IGF-1 remarkably enhanced c-Jun translo-
cations into the nucleus (Fig. 4c). Therefore, we propose
that the leucine zipper transcription-binding site is actually
an AP-1 site, and it can be specifically activated through the
JNK pathway downstream of the IGF-1 receptor.
AGR2-knockdown reduces IGF-1-induced cell
proliferation, migration and cell cycle progression
To further confirm how AGR2 induction contributes to IGF-
1-induced breast cancer development, we investigated
AGR2-knockdown effect on the IGF-1-induced cell prolif-
eration, cell migration and cell cycle distribution (Fig. 5).
We performed an AGR2-knockdown experiment using
specific short hairpin RNAs (shRNAs). MCF7 cells were
transfected with viral vectors carrying AGR2 shRNA and
were selected with puromycin for 14 days. Western blot
assays confirmed that AGR2 protein levels were significantly
reduced in two strains of MCF7 AGR2-knockdown cells
(shAGR2-1 and shAGR2-2), compared with those in cells
transfected with viral vectors alone (shControl) and normal
MCF7 cells (Fig. 5a). Additionally, RT-PCR assays revealed
the reduction of AGR2 at the mRNA level (Fig. 5b).
First, in an iCell proliferation assay, the data suggested
that IGF-1 treatment remarkably enhanced shControl cell
growth from 4 to 20 h. However, in shAGR2 cells, the
curve’s slope did not show significant changes after IGF-1
exposure over the same period (Fig. 5c). Second, we per-
formed a wound-healing assay on shControl and shAGR2-1/
2 cells (Fig. 5d). Strikingly, the results showed that shCon-
trol cells migrated into the wound significantly faster than
shAGR2 cells in the presence of IGF-1, whereas the mi-
gration rates in the absence of IGF-1 were almost equivalent.
We further conducted a flow cytometry assay with each cell
line with and without IGF-1 treatment for 24 h (Fig. 5e, f).
The data revealed a significant reduction in the proportion of
cell in G1 and an elevation of the proportion of cells in S
phase for shControl cells under IGF-1 treatment, compared
with those for shAGR2 cells. In all, we propose that the IGF-
1-induced anti-estrogen drug resistance requires AGR2, be-
cause AGR2 is involved in the regulation of cell prolif-
eration, migration and cell cycle progression by IGF-1.
Discussion
AGR2, as a novel biomarker for breast cancer, has already
become a recent research topic of interest. It has been
widely reported that AGR2 is highly involved in cancer
metastasis [18] and carcinogenesis [25]. However, in our
study, AGR2 knockdown in MCF7 cells did not show a
significant decrease in cell proliferation, migration or anti-
estrogen drug resistance. AGR2 knockdown does play a
significant role in IGF-1-induced cytological behaviors,
which indicates that AGR2 function may strongly depend
on the cancer microenvironment.
Our promoter analysis shown in Fig. 2 revealed that the
region of M6, from -894 to -888 bp on the AGR2 pro-
moter, whose specific element type and upstream pathway
were not detected, is likely an ER-interdependent region in
response to IGF-1. However, the regulatory intensity is less
than the leucine zipper region and ERE. Therefore, we
propose a transcriptional regulation model where the
AGR2 promoter responding to IGF-1 stimulation focuses
on the interaction between the three key elements, while
the regulation mechanism of M6 deserves further
investigation.
Our study also indicated that two cancer-related signal
cascades—ERK1/2 and AKT—are located at the upstream
of ER activation. We speculate that similar regulatory
pattern may also apply to other growth factors such as
EGF, VEGF, bFGF and PDGF in the regulation of AGR2
expression in ER-positive breast cancer, because these
growth factors are widely reported to be related to ERK1/2,
AKT or JNK pathway [26–28].
In Fig. 3a–f, AGR2 expression was effectively inhibited
by ICI while ER phosphorylation was elevated by ICI. It is
not a surprise because it has been reported that by binding
and inhibiting ER, ICI itself could induce the phosphory-
lation of ER [29] (seen in Fig. 3b, e). Since AKT inhibitor
and ERK1/2 inhibitor also abolish the IGF-1 signaling, for
anti-ER drug-resistant tumor with an elevated AGR2 level,
our study also indicated that targeting IGF-1/AGR2 path-
way might be a treatment strategy.
The potential clinical significance of our study is the
suggestion that evaluation of tumorigenesis risk in some
conditions is related to IGF-1 overexpression. It has been
reported that IGF-1 can be induced on certain circum-
stances, such as inflammatory bowel disease (IBD) [30],
myocardial infarction [31], growth hormone stimulation
[32] and diabetes [33]. Therefore, these diseases might
generate a potential link to increased cancer risk due to the
IGF-1 induction of AGR2.
Importantly, our results provide a novel mechanism of
IGF-1-induced anti-estrogen drug resistance. We introduce
AGR2 as a key modulator that is induced by IGF-1. The
induction mechanism mainly lies in an ERE and in an AP-1
site on the AGR2 promoter, through the ERK, AKT and
JNK pathway. Furthermore, the induction effect of IGF-1
to AGR2 leads to a promotion of cell proliferation and
migration.
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